Strong Topline, FX Gain Help Neimeth Return To Profitability

February 24, 2026
Strong Topline, FX Gain Help Neimeth Return To Profitability

Neimeth International Pharmaceuticals Plc recovered from a 2024 pretax loss following a strong topline growth and return to foreign exchange (FX) gain, which shielded the drugmaker from rising expenses.

The pharmaceutical company’s revenue grew by 64.28 percent to N7.36 billion in 2025, surpassing the N4.48 billion generated in 2024.

Join our WhatsApp Channel

In the same vein, Neimeth’s cost of production increased by 59 percent year-on-year, from N2.52 billion to N4.01 billion, according to the firm’s financial statements for the period ended December 31, 2025.

Consequently, the company closed the period under review with N3.34 billion gross profit, compared to the N1.95 billion recorded in 2024, representing a 71 percent growth.

However, other income declined to N1.09 billion in 2025, down by 23 percent from the N1.41 billion Neimeth recorded during the previous year.

Also, the company incurred N604,98 million marketing and distribution expenses, which dropped by 11 percent year-on-year, from N680.45 million, while administrative expenses increased by 88 percent, from N628.17 million to N1.17 billion.

But Neimeth reduced the impact of its expenses on the bottom line with a N48.11 million foreign exchange gain last year, recovering from the N2.04 billion FX loss recorded in 2024.

Following its impressive topline, coupled with FX gain, the drugmaker recorded N2.71 billion operating profit in 2025, surpassing the N18.88 million reported in 2024, indicating a 14,257 percent growth.

However, finance costs gulp a significant part of its earnings after increasing to N1.22 billion last year, up from the N873.32 million incurred on interest expenses and leases in 2024.

Despite the 40 percent increase in finance costs, Neimeth was able to achieve N1.48 billion profit before tax (PBT) in 2025, recovering from the N854.43 million pretax loss recorded the previous year.

Consequently, Neimeth’s tax expense jumped by 1,537.38 percent to N505.93 million during the period under review, up from the N30.89 million reported in 2024

As a result, the pharmaceutical company’s net profit was N982.12 million in 2025, compared to the N885.33 million loss after tax recorded in 2024.

For press releases, tip-offs, and corporate information, call 08149575257 (hotline), email: editor@primebusiness.africa and publisher@primebusiness.africa

+ posts

Leave a Reply

Your email address will not be published.

Previous Story

US Congress Backs Trump’s Nigeria CPC Redesignation, Unveils Tough Measures Over Christian Killings

Next Story

Trump Receives Report on Alleged Christian Genocide in Nigeria

Featured Stories

Latest from Business

NGX

NGX Market Cap Rises To N125.96trn — Up By N804.56bn

The market capitalisation of the Nigerian Exchange (NGX) increased by N804.56 billion to N125.96 trillion on Monday, February 23, from the N125.16 trillion recorded on Friday, February 20. The all-share index (ASI) expanded by 1,273.78 basis points, from 194,989.77 ASI to 196,263.55
Ellah Lakes Failing Where Presco, Okomu Oil Succeeded

Ellah Lakes Failing Where Presco, Okomu Oil Succeeded

In 2025, Ellah Lakes failed where its market rivals, Presco Plc and Okomu Oil Palm Plc, succeeded, leading to a decline in confidence of Nigerian Exchange (NGX) investors in the company’s growth prospects. Ellah Lakes had recorded a 642.72 percent increase in
Previous Story

US Congress Backs Trump’s Nigeria CPC Redesignation, Unveils Tough Measures Over Christian Killings

Next Story

Trump Receives Report on Alleged Christian Genocide in Nigeria

Don't Miss

Tinubu and South east leaders during visit

Tinubu’s Visit To The South-East: Governance Or Politics?

President Bola Tinubu’s recent visit to Enugu marks a pivotal

Mission X: Madugu Picks Ajibade, Nnadozie, Ordega, Oshoala, 20 Others for Morocco 2024

Head Coach Justine Madugu has unveiled Nigeria’s squad for the